Introduction {#sec2}
============

Polycystic ovary syndrome (PCOS) represents a heterogeneous condition often including ovulatory dysfunction, hyperandrogenemia and characteristic alterations in ovarian morphology, and is present in 6--15% of all women of reproductive age ([@ref23]; [@ref72]). Obesity, insulin resistance, dyslipidemia and type 2 diabetes mellitus are all features frequently associated with PCOS ([@ref44]; [@ref23]). In addition, PCOS often runs in families ([@ref37]; [@ref31]), suggesting a genetic component ([@ref9]; [@ref65]; [@ref16]).

PCOS is often diagnosed in women who wish to conceive. Recent research revealed that even during singleton pregnancies, women with PCOS present with increased pregnancy complication rates, such as gestational diabetes mellitus, pregnancy induced hypertension and pre-eclampsia ([@ref7]). Moreover, neonates born from women with PCOS present with increased neonatal complication rates, especially resulting from preterm birth ([@ref7]; [@ref51]; [@ref11]).

The Barker hypothesis implies that the health and development of children is directly affected by the intrauterine environment ([@ref6]; [@ref33]; [@ref50]). An association between maternal health and offspring health has been convincingly demonstrated in the general population ([@ref57]; [@ref73]; [@ref25]). The maternal influence is hypothesized to be exerted via fetal programming, which occurs *in utero* during critical development stages in early embryonic and fetal life ([@ref36]). Fetal programming may affect male and female fetuses differently in the intrauterine environment. Animal studies, for example, report on higher offspring blood pressure in males compared to females in response to maternal pharmacological glucocorticoid administration during gestation ([@ref21], [@ref20]). However, in human studies concerning adiposity in offspring, female offspring appear to be more sensitive to increased maternal glucose levels ([@ref56]).

Currently, limited information is available regarding health of the offspring of women with PCOS (OPCOS). The sample size of the studies in OPCOS is rather small and the possibility to adjust for confounding factors is therefore limited. The majority of human studies in PCOS predominantly report on female offspring. Moreover, existing literature concerning metabolic outcomes in OPCOS is inconsistent. For example, the increased insulin concentrations found in the American and Chilean OPCOS ([@ref63]; [@ref32]; [@ref38]) were not observed in Dutch children from mothers with PCOS ([@ref18]). Cardiometabolic derailments in childhood are often subtle, but may still have distinct implications for cardiovascular health in adulthood ([@ref15]; [@ref4]; [@ref61]). In two studies including both female and male offspring, no sex differences were observed in anthropometrics, lipid profile or glucose and insulin concentrations in serum ([@ref32]; [@ref18]).

Therefore, the primary purpose of the current systematic review and individual participant data (IPD) meta-analysis was to compare cardiometabolic health in the children of women previously diagnosed with PCOS to healthy controls. Second, we aim to explore whether any differences in metabolic and other factors in female and male OPCOS exist. An IPD meta-analysis was conducted to increase the power to detect potential differences. We hypothesize that OPCOS exhibit worse increased insulin concentrations compared to healthy controls.

Methods {#sec3}
=======

We conducted our systematic review according to PRISMA guidelines ([@ref43a]). A systematic search in the PubMed and EMBASE was performed on 1 June 2016 and last updated on 1 February 2018. Relevant key terms such as 'offspring' and 'polycystic ovarian syndrome' and serum hormones such as 'glucose' and 'insulin' were combined in a search syntax with the use of database specific subject headings (e.g. MeSH-terms in PubMed). There was no methodological search term (e.g. 'cohort' or 'case-control') added to the search syntax, because we expected little added value in the completeness of the articles retrieved by our search ([Supplementary Table S1](#sup3){ref-type="supplementary-material"}). We also conducted an online gray literature search. Duplicates were removed electronically and manually by using Mendeley software. The full search terms are listed in the [Supplementary Table SI](#sup3){ref-type="supplementary-material"}. The study protocol is registered at PROSPERO with number: CRD42019117798 (<http://www.crd.york.ac.uk/PROSPERO/>).

Study selection {#sec4}
---------------

We selected studies on children of women with PCOS. PCOS diagnosis must be performed by a physician in a standardized fashion in all mothers of the included children. We included studies with children between 1 and 18 years of age, regardless of sex. Studies reporting on children in the neonatal period were excluded because they mainly focused on pregnancy and perinatal outcomes ([@ref2]). We intended to focus on features potentially relevant for prediction of long-term health outcomes: BMI, blood pressure, fasting and post-load (after oral glucose administration) levels of serum glucose and insulin, and lipid profile. Only human studies with original data were eligible for inclusion. All English, Dutch, German, French and Spanish publications were included. Commentaries, opinion papers, case reports, small case series (*n* \< 10) and systematic reviews were not eligible for inclusion. We used similar criteria for title and abstract screening as for the full text screening. Authors who independently performed the screening (M.N.G., M.A.W. and J.P.C.) endorsed the final selection of articles. A fourth author (B.C.J.M.F.) was available when consensus on final article selection was not achieved. The final step in study selection was performing a thorough check of the reference lists of all relevant articles, regardless of design, in the search (cross reference checking) ([Fig. 1](#f1){ref-type="fig"}).

![Flowchart of the search, according to PRISMA guidelines. ^\*^ = all data in this step were available obtained and analyzed, *n* = number. All numbers (*n*) mentioned in the exclusion criteria were extracted in the 'screening on full-text' step (Figure adjusted from the PRISMA group (Moher 2009).](dmz036f1){#f1}

Risk of bias assessment {#sec5}
-----------------------

Internal validity of the individual studies was assessed using the Newcastle Ottawa Quality Assessment Scale (NOS). The NOS is recommended for observational studies, which was the expected study design for our research question ([@ref66]). The three main categories of the NOS are: selection of patients and controls, comparability of patients and controls and exposure of both groups. The NOS has the possibility to add study specific elements to its criteria. Considering our hypothesis, we chose to specifically assess the adjustment for age, sex and socio-economic status. Each study separately received a risk of bias level: high (1--3 stars), medium (4--6 stars) or low (7--9 stars) ([Supplementary Table SII).](#sup3){ref-type="supplementary-material"}

Data collection {#sec6}
---------------

Authors of studies eligible for inclusion in our IPD meta-analysis were invited to join our study and share their data. As previously published, the research groups received approval for the individual studies from the local medical ethics committee. Requested data comprised continuous data on maternal characteristics, birthweight of their offspring and data on the cardiometabolic status of the offspring. An exception was dichotomous data on sex, gestation (multiple/singleton) and presence of siblings in the dataset. Received data were uniformly coded and harmonized in one dataset ([Figs 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). We converted all serum concentrations into similar units of measure. The Dutch data on glucose and lipid profiles were converted from millimole per liter (mmol/L) to milligram per deciliter (mg/dL) ([@ref26]). No further harmonization issues had to be encountered.

![Flowchart of the study: from systematic search results to IPD dataset. This flowchart represents the four steps (four columns' from left to right), which were undertaken to collect our final data for the IPD meta-analysis. Column (1) Participants (*n*) per study. Our screening resulted in nine publications from three research groups with (*n*) participants per article (cases and controls together). Column (2) Received data. Each research group shared one file with all offspring of women with PCOS (OPCOS) and all healthy controls (*n*), which showed that some subjects participated in more than one publication. Column (3) Extraction \<1 yr (year) and duplicates. In the third step, we excluded all children below 1 year old and all duplicate children (children who were screened multiple times). Column (4) IPD analysis *n* = 885. In the fourth step, a dataset remained with 885 unique children aged 1--18 years (OPCOS and controls), on which we conducted our IPD meta-analyses.](dmz036f2){#f2}

![Parameters measured per age category in all included centers. Total number of included children on their first visit is 885: for two children their age and sex is missing. (*n*) = number of children in which the parameter is available.](dmz036f3){#f3}

The outcomes were parameters of the cardiometabolic profile of offspring: age- and sex-corrected BMI and systolic blood pressure (SBP), and age-corrected fasting and post-load insulin and glucose concentrations, homeostatic model assessment for insulin resistance (HOMA-IR), total-cholesterol, triglycerides, low/high-density lipoprotein-cholesterol (LDL/HDL-c) concentrations and composites of the aforementioned offspring parameters: the metabolic sum scores. We calculated HOMA-IR levels if not yet present in the received datasets, which is a measure for insulin resistance (HOMA-IR = \[fasting insulin (μU/ml)^\*^fasting glucose (mmol/liter)\]/405) ([@ref43]). Due to the lack of consensus on how to define the metabolic syndrome in children, we calculated two different metabolic sum scores, a summation of multiple standardized scores (SDS) ([@ref22]). First, we calculated metabolic sum score-1, a composite of BMI, SBP, fasting insulin, triglycerides and HDL-c. Second, we calculated metabolic sum score-2, a composite of waist-to-height ratio, SBP, glucose, triglycerides and HDL-c. Metabolic sum score-2 was previously used in a large Dutch cohort study ([@ref49]).

Statistical analysis {#sec7}
--------------------

Continuous normally distributed data were summarized with a mean and SD, and if non-normally distributes a median and interquartile range (IQR) were used. Categorical variables were summarized by number and percentage. We used the square root of fasting and post-load insulin concentrations and HOMA-IR, since these variables were non-normally distributed.

For missing baseline characteristics, multiple imputations (*n* = 5) following the predictive mean matching principal was used. We calculated age-specific SDS based on the control population for all metabolic parameters. We used the World Health Organization (WHO) reference standards of 2007 to calculate the BMI SDS for each child using a WHO tool: WHO Anthro version 3.2.2, January 2011 ([@ref70], [@ref69]). The BMI SDS accounts for the age and sex of the child and is universally applicable. We also calculated age- and sex-dependent SBP percentiles according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents ([@ref46]). Percentiles were transformed to SDS, which were used for analyses.

Conversion of metabolic markers, as described previously, took place before pooling all data ([@ref26]).

Heterogeneity among studies was assessed by constructing Forest plots and performing a Chi^2^-test. We also evaluated potential publication bias by constructing Funnel plots. For both plots, we used the metabolic sum score-1 (composite SDS of: BMI, SBP, fasting insulin, triglycerides and HDL-c) of the first visits of all children and the total number of visits of the children separately. The software utilized was [@ref56a]).

To answer our research question on cardiometabolic outcomes in OPCOS versus controls, we used a one-step approach and constructed a linear mixed model with a random effect for the country or research group the children originated from. By correcting for country of origin, we take international differences, such as anthropometric and assay differences, into account.

In the first analyses, we analyzed differences between OPCOS and controls, regardless of sex, in a basic (models 1, 3, 5 and 7) and an adjusted model (models 2, 4, 6 and 8).

For birthweight, we adjusted in a basic model only for gestational age and the country (USA, Chile or The Netherlands) from which the children originated (model 1). In the adjusted model, we additionally corrected birthweight for sex, parity, multiple gestation and presence of siblings in this study (model 2).

In two variables, we calculated SDS using external reference populations: WHO-based BMI SDS and the Centers for disease control and prevention (CDC)-based SBP SDS. In the WHO-based BMI SDS, the age and sex of the child are already taken into account and in the basic model and we additionally corrected for the country from which children originated (model 3). In the adjusted model, we also adjusted for parity, multiple gestation and presence of siblings in this study (model 4). In the CDC-based SBP SDS, sex, height and age were already taken into account and we additionally adjusted for the country from which children originated (model 5). In the adjusted model, we added similar factors as for the adjusted model with BMI SDS, with addition of the weight of the offspring (model 6). For all other outcomes, in the basic model, we adjusted for age of the child and the country from which the children originated (model 7). In the adjusted model, we additionally corrected for sex of the child, parity of the mother, multiple gestation and whether children had any siblings in the IPD meta-analysis included (model 8).

Second, we added interaction terms to the additionally adjusted mixed models (models 2, 4, 6 and 8) to evaluate whether sex was an effect modifier in the association between the exposure variable (a mother with or without PCOS diagnosis) and the dependent variables (the cardiometabolic outcomes). The *P*-values presented are the results of the interaction test. We provided estimated mean differences with a 95% CI of OPCOS versus controls, and of the male and female children separately, without *P*-values. All data were analyzed using SPSS Statistics, version 25.0 (IBM SPSS Inc., Chicago, IL, USA). Owing to the number of statistical tests we performed, a Bonferroni correction for multiple testing ([@ref10]) was applied. Three independent cardiometabolic outcomes were tested: anthropometrics, insulin resistance and lipid profile: outcomes were divided in these three clusters. Therefore, the significance level *P* = 0.05 was divided by three, which provides a significance level corrected for multiple testing: *P* = 0.017.

Results {#sec8}
=======

Search results {#sec9}
--------------

The systematic search identified a total of 1931 articles, of which nine articles were selected for internal validity assessment ([Fig. 1](#f1){ref-type="fig"}, [Supplementary Table SIII](#sup3){ref-type="supplementary-material"}). Risk of bias assessment using the NOS revealed six articles with a medium risk of bias and three articles with low risk of bias ([Table I](#TB1){ref-type="table"}).

###### Internal validity of included studies using the NOS for assessing the quality of observational studies^a^.

  -------------------------------------------------------------------------------------------------------------------------------------
  Study                       Selection   Comparability\          Exposure   Total risk of bias\                                    
                                          of cases and controls              (number of stars)                                      
  --------------------------- ----------- ----------------------- ---------- --------------------- ----------- ------ ------ ------ ---
  [@ref13a]                   ^\*^        ^\*^                    NR         ^\*^                  ^\*^ ^\*^   ^\*^   ^\*^   NR     7

  Sir-Petermann et al. 2007   ^\*^        ^\*^                    NR         ^\*^                  ^\*^        ^\*^   ^\*^   NR     6

  Recabarren et al. 2008      ^\*^        ^\*^                    NR         ^\*^                  ^\*^ ^\*^   ^\*^   ^\*^   NR     7

  [@ref40a]                   ^\*^        ^\*^                    NR         ^\*^                  \-          ^\*^   ^\*^   NR     5

  Sir-Petermann et al. 2009   ^\*^        \-                      NR         ^\*^                  ^\*^        ^\*^   ^\*^   NR     5

  Kent et al. 2008            ^\*^        \-                      ^\*^       ^\*^                  ^\*^        ^\*^   ^\*^   NR     6

  Legro et al. 2017           ^\*^        NR                      NR         ^\*^                  ^\*^ ^\*^   ^\*^   ^\*^   NR     6

  Crisosto *et al*. 2017      ^\*^        ^\*^                    NR         ^\*^                  ^\*^        ^\*^   ^\*^   NR     6

  De Wilde et al. 2018        ^\*^        \-                      ^\*^       ^\*^                  ^\*^ ^\*^   ^\*^   \-     ^\*^   7
  -------------------------------------------------------------------------------------------------------------------------------------

See also [Supplementary Table SII](#sup3){ref-type="supplementary-material"}.

- = study did not receive a star for this item, ^\*^ = study receives a star for this item, total risk of bias: 1--3 stars = high, 4--6 stars = medium, 7--9 stars = low; NR = not reported.

Baseline characteristics {#sec10}
------------------------

A total of 1367 children participated in the identified studies eligible for this IPD meta-analysis. Multiple children participated several times during their childhood. However, we chose to use only the first visit of all children to avoid any possible inclusion bias, i.e. an over presentation of children with an unfavorable measurement outcomes. Therefore, only 885 cardiovascular screenings of unique children OPCOS = 298 (female *n* = 196, male *n* = 102), controls *n* = 587 (female: *n* = 354, male: *n* = 233) were used for the current mixed model analysis ([Fig. 2](#f2){ref-type="fig"}).

Mean age of the OPCOS group was 8.1 years old (SD 3.7) and of the healthy controls 7.9 years old (SD 3.7). Mean BMI was 18.8 kg/m^2^ (SD 4.5) in OPCOS and for the control group 18.1 kg/m^2^ (SD 3.8). Mean age and BMI among mothers with PCOS was 35.7 years old (SD 6.0) and 32.4 kg/m^2^ (SD 8.6) and among the controls 38.1 years old (SD 5.3) and 24.8 kg/m^2^ (SD 4.2), respectively. The Tanner stages were reported by the American research group: ([@ref32]) and the Chilean research group, presented in [Table II](#TB2){ref-type="table"} ([@ref62]). The Chi^2^-tests for heterogeneity of our study population was not significant (*P* = 0.42) and accompanied by a non-significant effect on the metabolic sum score-1 status between OPCOS and healthy controls (*P* = 0.55). The Funnel plot reported no clear sign of publication bias ([Supplementary Figs SI](#sup1){ref-type="supplementary-material"} and [SII](#sup2){ref-type="supplementary-material"}).

###### Baseline characteristics of all 885 first visits of offspring of women with PCOS and controls in this IPD analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                          Sir-Peterman\            Legro\               De Wilde\                                                      
                                                          et al. -- Chilean data   et al. -- USA data   et al. -- Dutch data                                           
  ------------------------------------------------------- ------------------------ -------------------- ---------------------- ------------------- ------------------- -------------------
  *Baseline at birth*                                                                                                                                                  

  Sex (% girls)                                           70 (59)                  80 (47)              90 (86)                103 (86)            36 (48.6)           171 (57.4)

  Gestational age (weeks), median (IQR)                   39.0 (38.0--40.0)        39.0 (38.0--40.0)    40.0 (39.0--40.0)      40.0 (40.0--40.0)   39.1 (38.2--40.4)   39.6 (39.0--40.6)

  Birthweight (grams), mean (±)                           3287 ± 589               3323 ± 515           3726 ± 637             3806 ± 637          3304 ± 648          3569 ± 488

  Multiple gestation (%)                                  0 (0%)                   0 (0%)               2 twin pairs (1%)      1 twin pair (2%)    2 twin pairs (5%)   4 twin pairs (3%)

  *Screening during childhood*                                                                                                                                         

  Age at screening (year), mean (±)                       9.1 ± 3.6                10.4 ± 3.1           9.2 ± 3.5              10.2 ± 3.6          4.9 ± 2.0           5.6 ± 2.2

  BMI (kg/m^2^), median (IQR)                             19.3 (16.7--22.4)        20.1 (17.4--22.8)    19.8 (15.8--22.4)      19.6 (16.1--21.9)   15.6 ± 1.6          16.1 ± 1.5

  Waist (cm), median (IQR)                                62 (56--72)              66 (60--73)          62 (55--74)            66 (56--75)         52 (50--55)         55 (52--58)

  Waist to height ratio, mean (±)                         0.49 ± 0.1               0.47 ± 0.1           0.48 ± 0.1             0.47 ± 0.1          0.48 ± 0.1          0.48 ± 0.1

  SBP (mm Hg), mean (±)                                   91 ± 11                  93 ± 13              106 ± 14               107 ± 11            98 ± 8              99 ± 9

  DBP (mm Hg), mean (±)                                   56 ± 9                   57 ± 10              65 ± 8                 65 ± 8              51 ± 7              52 ± 6

  Fasting glucose (mg/dL), mean (±)                       83 ± 10                  83 ± 9               78 ± 10                78 ± 12             84 ± 6              82 ± 11

  Fasting 2-hour glucose (mg/dL),\                        99 ± 24                  95 ± 17              86 ± 20                82 ± 17             NA                  NA
  mean (±)                                                                                                                                                             

  Fasting insulin (μU/ml), median (IQR)                   8 (5--14)                10 (6--14)           15 (6--21)             13 (7--15)          4 (2--5)            5 (4--7)

  Fasting 2-hour insulin (μU/ml), median (IQR)            33 (13--63)              32 (18--51)          52 (31--86)            49 (28--67)         NA                  NA

  HOMA-IR, median (IQR), median (IQR)                     2.3 (1.1--2.8)           2.0 (1.2--2.8)       3.3 (1.2--4.1)         2.5 (1.3--2.0)      0.9 (0.5--1.2)      1.1 (0.7--1.4)

  LDL-cholesterol (mg/dL), mean (±)                       93 ± 31                  90 ± 35              58 ± 25                55 ± 21             120 ± 48            106 ± 24

  Total cholesterol (mg/dL), mean (±)                     157 ± 30                 167 ± 31             150 ± 29               145 ± 12            189 ± 51            170 ± 27

  HDL-cholesterol (mg/dL), mean (±)                       44 ± 13                  42 ± 10              84 ± 53                69 ± 32             56 ± 12             56 ± 10

  Triglycerides (mg/dL), mean (±)                         114 ± 45                 116 ± 36             85 ± 27                82 ± 30             62 ± 21             42 ± 18

  Metabolic sum score-1 (SDS), mean (±)                   1.5 ± 2.9                1.0 ± 2.7            0.5 ± 4.0              1.6 ± 2.2           −0.9 ± 1.2          −1.3 ± 2.0

  Metabolic sum score-2 (SDS), mean (±)                   0.2 ± 2.6                0.1 ± 2.4            −1.4 ± 4.3             −0.3 ± 1.9          −0.9 ± 1.1          −1.6 ± 1.8

  Tanner stage: pubic hair                                NA                       NA                   1 (1--2)               1 (1--3)            NA                  NA

  Tanner stage: breasts                                   2 (1--4)                 2 (1--4)             1 (1--3)               1 (1--4)            NA                  NA

  Tanner stage: testis                                    2 (1--3)                 2 (1--4)             2 (0--4)               1 (0--2)            NA                  NA

  Maternal age during screening child (years), mean (±)   34.6 ± 7.2               37.9 ± 6.8           35.6 ± 5.8             NA                  37.0 ± 4.4          38.2 ± 4.6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PCOS: polycystic ovary syndrome, SBP/DBP = systolic/diastolic blood pressure, NA = not available data, SDS = standardized deviation score, WHO = World Health Organization. Baseline characteristics in: *n* (%), mean (±: SD) or median with interquartile range (IQR): 25--75th percentile.

Outcomes in all children {#sec11}
------------------------

The basic model revealed a lower birth weight in OPCOS versus controls (*β* = −129 (95%CI:−208---51), *P* \< 0.01). Furthermore, a higher fasting insulin (*β* = 0.21(95%CI:0.03--0.40), *P* = 0.03) and 2 hour post-load insulin (*β* = 0.27(0.01--0.53), *P* = 0.04), HOMA-IR (*β* = 0.23(0.03--0.44), *P* = 0.02), triglycerides (*β* = 0.21(0.05--0.38), *P* = 0.01) and HDL-cholesterol (*β* = 0.31(0.09--0.54), *P* \< 0.01) were identified in the OPCOS group ([Table III](#TB3){ref-type="table"}). However, after correction for multiple testing only birthweight, triglycerides and HDL-cholesterol remained significant.

###### Cardiometabolic profile parameters recorded at all 885 first visits (229 males, 550 females), analyzed by using mixed model analysis unstratified for sex of the offspring.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                                                    PCOS: *n* = 298   Controls:\    Basic model\                                            *P*                  Adjusted model -- Estimated difference: PCOS versus controls (95%CI)   Adjusted *P*
                                                                                *n* = 587     -- Estimated difference: PCOS versus controls (95%CI)                                                                                               
  ----------------------------------------------------------- ----------------- ------------- ------------------------------------------------------- -------------------- ---------------------------------------------------------------------- --------------------
  *Anthropometrics*                                                                                                                                                                                                                               

  Birth weight (g)                                            3446(653)         3555(554)     **−129(−208 to −51)**                                   **\<0.01^\*\*\*^**   **−116(−195 to −38)**                                                  **\<0.01^\*\*\*^**

  BMI SDS (WHO references)                                    0.84(1.25)        0.64(1.13)    0.03(−0.05 to 0.12)                                     0.68                 0.03(−0.14 to 0.19)                                                    0.74

  Waist to height ratio (WtHR)                                0.08(1.21)        0.08(1.01)    0.03(−0.13 to 0.19)                                     0.70                 0.03(−0.13 to 0.18)                                                    0.73

  Waist SDS                                                   0.21(3.39)        0.00(1.01)    0.02(−0.14 to 0.18)                                     0.81                 0.01(−0.15 to 0.18)                                                    0.87

  SBP SDS                                                     −0.15(1.25)       −0.16(1.16)   0.12(−0.04 to 0.29)                                     0.15                 0.14(−0.03 to 0.31)                                                    0.11

  *Endocrine markers*                                                                                                                                                                                                                             

  Fasting glucose SDS                                         −0.03(0.96)       −0.04(0.99)   0.04(−0.14 to 0.22)                                     0.68                 0.04(−0.14 to 0.22)                                                    0.68

  Fasting insulin^\*^ SDS                                     0.39(1.0)         −0.03(1.00)   **0.21(0.03 to 0.40)**                                  **0.03**             **0.21(0.01 to 0.41)**                                                 **0.05**

  HOMA-IR^\*^ SDS                                             0.39(1.28)        −0.03(1.00)   **0.23(0.03 to 0.44)**                                  **0.02**             **0.21(0.01 to 0.42)**                                                 **0.04**

  Fasting 2 hour glucose SDS                                  −0.69(0.54)       −0.68(0.58)   −0.03(−0.13 to 0.08)                                    0.64                 −0.02(−0.13 to 0.09)                                                   0.72

  Fasting 2 hour insulin^\*^ SDS                              0.29(1.29)        0.02(1.04)    **0.27(0.01 to 0.53)**                                  **0.04**             0.20(−0.09 to 0.49)                                                    0.18

  *Lipid profile*                                                                                                                                                                                                                                 

  LDL-cholesterol SDS                                         −0.26(1.11)       −0.04(1.00)   −0.07(−0.26 to 0.11)                                    0.46                 −0.09(−0.28 to 0.10)                                                   0.37

  Total cholesterol SDS                                       −0.10(1.03)       −0.01(0.99)   −0.01(−0.21 to 0.20)                                    0.96                 −0.05(−0.25 to 0.15)                                                   0.66

  HDL-cholesterol SDS                                         0.34(1.87)        0.08(1.02)    **0.31(0.09 to 0.54)**                                  **\<0.01^\*\*\*^**   **0.31(0.08 to 0.54)**                                                 **\<0.01^\*\*\*^**

  Triglycerides (TG) SDS                                      0.35(1.03)        −0.08(0.98)   **0.21(0.05 to 0.38)**                                  **0.01^\*\*\*^**     **0.19(0.02 to 0.36)**                                                 **0.03**

  *Cardiometabolic health*                                                                                                                                                                                                                        

  Metabolic sum score-1: *BMI + SBP + INSULIN + TG ± HDL*     0.89(3.27)        −0.14(2.65)   0.29(−0.40 to 0.61)                                     0.38                 0.30(−0.36 to 0.95)                                                    0.38

  Metabolic sum score-2: *WtHR + SBP + Glucose + TG + −HDL*   −0.52(3.33)       −0.82(2.24)   0.08(−0.52 to 0.68)                                     0.80                 0.18(−0.43 to 0.80)                                                    0.56
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^ = square root of fasting insulin and HOMA-IR, ^\*\*^ = in the Methods section the rationale was postulated for the models used, ^\*\*\*^ = *P*-value remained significant after correction for multiple testing, Bold text = P-values below 0.05, HOMA-IR = (\[fasting insulin (μU/ml)^\*^fasting glucose (mmol/liter)\]/405) (Matthews 1985)\], SDS = *z*-score.

Outcomes are presented in standardized (except for birthweight) mean estimated differences with a 95%CI and *P*-value: offspring of women with PCOS versus controls. We tested a basic and an adjusted model, as follows.

***Models used^\*\*^**:* In the basic model (model 1), birthweight was adjusted for gestational age and country from which the children originated (USA, Chile or The Netherlands). And in the adjusted model (model 2), we additionally adjusted for sex, parity, multiple gestation and presence of siblings in this study.

In two variables, we calculated SDS using an external reference population: WHO-based BMI SDS and the CDC-based SBP. In the WHO-based BMI SDS, the age and sex of the child are taken into account in the basic model (model 3) and we additionally adjusted for country from which children originated. In the adjusted model (model 4), we also adjusted for parity, multiple gestation and presence of siblings in this study. In the CDC-based SBP SDS: sex, height and age were taken into account and we additionally adjusted for country from which children originated (model 5). In the adjusted model (model 6), we added similar factors as in BMI SDS, with the addition of the offspring weight.

For all other outcomes: in the basic model (model 7), we adjusted for: age of the child and the country from which the children originated (USA, Chile or The Netherlands). In the adjusted model (model 8), we additionally corrected for sex of the child, parity of the mother, multiple gestation and whether children had any siblings in the IPD included.

In all variables, with exception for birthweight, SDS was used.

*P*-value \<0.017 was considered significant, as we had to correct our analysis for multiple testing (*P*-value of 0.017 was calculated as: 0.05 divided by 3).

Analysis with the adjusted model revealed that OPCOS (*n* = 298) exhibited increased plasma levels of fasting insulin (*β* = 0.21(95%CI:0.01--0.41), *P* = 0.05), insulin-resistance (*β* = 0.21(95%CI:0.01--0.42), *P* = 0.04), triglycerides (*β* = 0.19(95%CI:0.02--0.36), *P* = 0.03) and HDL-cholesterol concentrations (*β* = 0.31(95%CI: 0.08--0.54), *P* \< 0.01), but reduced birthweight (*β* = −116(95%CI: −195 to 38), *P* \< 0.01) compared to controls (*n* = 587). After correcting for multiple testing, only the differences in HDL-cholesterol and birthweight remained significant ([Table III](#TB3){ref-type="table"}).

Effect modification by sex in metabolic profile in offspring of women with or without PCOS {#sec12}
------------------------------------------------------------------------------------------

We also investigated in the adjusted models whether effect modification by sex of the child played a role in the association between offspring status (PCOS mother or mother without PCOS) and cardiometabolic outcome. This was the case for 2 hour post-load insulin, LDL-cholesterol, total cholesterol, HDL-cholesterol and both metabolic sum scores ([Table IV](#TB4){ref-type="table"}). However, after correction for multiple testing, only the interaction test for LDL-cholesterol, total cholesterol, HDL-cholesterol and metabolic sum score-1 remained significant. In brief, female OPCOS presented with lower LDL-cholesterol, lower total cholesterol and lower metabolic sum score-1 compared to female controls, compared to the mean difference among males. HDL-cholesterol differences were slightly larger in female OPCOS versus controls, compared to the difference among males ([Table IV](#TB4){ref-type="table"}).

###### Cardiometabolic profile parameters of all 885 first visits stratified for sex of the offspring and assessed by mixed model analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                                                  Male PCOS offspring\                            Female PCOS offspring\                         Interaction term for sex difference: PCOS versus controls *P*-value
                                                            versus controls: Estimated difference (95%CI)   versus controls: Estimate difference (95%CI)   
  --------------------------------------------------------- ----------------------------------------------- ---------------------------------------------- ---------------------------------------------------------------------
  *Anthropometrics*                                                                                                                                        

  Birthweight (grams)                                       −69(−174 to 35)                                 −126(−232 to 21)                               0.68

  BMI SDS: WHO reference                                    −0.10(−0.37 to 0.18)                            0.11(−0.21 to 0.59)                            0.45

  WtHR SDS                                                  0.03(−0.20 to 0.26)                             0.03(−0.18 to 0.24)                            0.73

  Waist SDS                                                 −0.03(−0.28 to 0.21)                            0.05(−0.16 to 0.25)                            0.71

  SBP SDS                                                   0.30(−0.01 to 0.62)                             0.04(−0.16 to 0.25)                            0.09

  *Endocrine markers*                                                                                                                                      

  Fasting glucose SDS                                       0.03(−0.20 to 0.27)                             −0.01(−0.27 to 0.27)                           0.98

  Fasting insulin SDS                                       0.11(−0.16 to 0.38)                             0.21(−0.08 to 0.49)                            0.88

  HOMA-IR SDS                                               0.11(−0.16 to 0.37)                             0.22(−0.07 to 0.51)                            0.75

  Fasting 2 hour glucose SDS                                −0.03(−0.16 to 0.10)                            −0.02(−0.18 to 0.13)                           0.75

  Fasting 2 hour ^\*^insulin SDS                            −0.20(−0.58 to 0.19)                            **0.45(0.07 to 0.83)**                         **0.03**

  *Lipid profile*                                                                                                                                          

  LDL-cholesterol SDS                                       0.27(−0.03 to 0.57)                             **−0.39(−0.62 to −0.16)**                      **\<0.01^\*\*\*^**

  Total cholesterol SDS                                     0.28(−0.01 to 0.56)                             **−0.31(−0.57 to −0.06)**                      **0.01^\*\*\*^**

  HDL-cholesterol SDS                                       0.13(−0.05 to 0.31)                             **0.53(0.18 to 0.88)**                         **\<0.01^\*\*\*^**

  TG SDS                                                    0.12(−0.11 to 0.34)                             0.26(0.01 to 0.51)                             0.52

  *Cardiometabolic health*                                                                                                                                 

  Metabolic sum score-1 *BMI + SBP + INSULINE + TG + HDL*   0.85(−0.10 to 1.79)                             −0.14(−1.05 to 0.77)                           **\<0.01** ^\*^ ^\*^ ^\*^

  Metabolic sum score-2: *WtHR+SBP + Glucose + TG + HDL*    0.64(−0.17 to 1.45)                             −0.19(−1.12 to 0.74)                           **0.02**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Outcomes are presented in mean estimated differences with a 95%CI: PCOS offspring versus controls. We tested whether sex of the child was a significant mediator, when comparing PCOS offspring versus controls.

^\*^ = square root of insulin, ^\*\*\*^ = *P*-value remained significant after correction for multiple testing. Bold text = P-values below 0.05*.*

***Models used:*** In birthweight, we adjusted for country from which the children originated, gestational age, siblings in the dataset and multiple gestation.

In SBP, we adjusted for: country from which the children originated, gestational age, multiple gestation, siblings in the dataset, age of the child and BMI of the child. In all remaining parameters, we adjusted for country from which the children originated, gestational age, multiple gestation, siblings in the dataset and age of the child.

*P*-value \< 0.017 was considered significant, as we had to correct our analysis for multiple testing (*P*-value of 0.017 was calculated as: 0.05 divided by 3). The *P*-value was the result of the interaction test for sex; we did not report mean estimated differences for the interaction test. The estimated differences (95%CI) presented in this table for males and females separately are the differences in male PCOS offspring versus male controls, and female PCOS offspring versus female controls. We refrained from the reporting of *P*-values for these secondary analyses.

Discussion {#sec13}
==========

The current systematic review of the literature and subsequent IPD meta-analysis was designed to assess whether OPCOS present with less favorable cardiometabolic features compared to offspring of healthy controls. First, the adjusted IPD analyses of all initial offspring screenings (*n* = 885) demonstrated that OPCOS (*n* = 298) exhibited significantly increased fasting insulin and insulin resistance, HDL-cholesterol and triglyceride concentrations, but lower birthweight compared to controls (*n* = 587). However, after correction for multiple testing, only the mean differences in birthweight and HDL-cholesterol remained significant. Second, we identified significant effect modification by sex in 2 hour post-load insulin, LDL-cholesterol, total cholesterol, HDL-cholesterol and both metabolic sum scores. After correction for multiple testing, effect modification by sex was only statistically significant in LDL-cholesterol, total cholesterol, HDL-cholesterol and metabolic sum score-1. Only in the female offspring did we observe estimated differences (95%CI) that did not contain the neutral value; female OPCOS have a higher insulin concentration and HDL-cholesterol, but a lower LDL-cholesterol and total cholesterol compared to female controls.

This study demonstrates that PCOS and its associated features in the mothers have implications for offspring health, with potential sex-dependent alterations in metabolic profiles in childhood. These conclusions were based on data of individual studies of level IV evidence (data of case-control studies), which reflects the need for high-validity studies on the metabolic health of children from mothers with PCOS ([@ref59]).

In the current study, we also investigated whether birthweight differed between OPCOS and controls. Birthweight is of interest due to its direct link with cardiovascular disease (CVD) later in life and in adulthood ([@ref29]). Conditions of the intra-uterine environment are partially reflected in birthweight ([@ref6]). The lower birthweight observed in OPCOS compared to controls is in agreement with a meta-analysis conducted earlier by our research group involving both high- and low-quality studies ([@ref7]). This effect could be mediated to some extent by an increased incidence of pre-eclampsia next to maternal metabolic dysfunction ([@ref7]; [@ref12]). The definition of low birthweight according to WHO is a birthweight below 2500 g, independent of gestational age. Only 3.6% of all infants in our study had a low birthweight; 5.1% in the OPCOS and 2.9% in the controls. This difference was not statistically significant. Therefore, we do not expect the cardiovascular profiles to deviate solely because of differences in birthweight, in this study ([@ref71]).

BMI, waist-to-height-ratio, waist circumference and blood pressure in OPCOS were comparable to the measurements in controls, despite the well-known increased incidence of obesity among adult women diagnosed with PCOS ([@ref64]). Only one of the included Chilean studies reported that BMI of OPCOS was significantly higher compared to the BMI of controls ([@ref55]). Waist circumference in Dutch children participating in the current study was smaller compared to the American and Chilean offspring, and blood pressure was systematically higher in Dutch and American compared to Chilean offspring. Differences in BMI and blood pressure between studies potentially reflect the influence of intercontinental differences in the IPD meta-analysis, which were considered in our analyses by correcting for the continent the offspring originated from. The reference data we used for BMI from WHO were based on a multi-ethnic dataset with children from Brazil, Ghana, India, Norway, Oman and the USA. We believe that since North-America, South-America and North-Europe were represented in this reference data, generalizability of the reference data to the IPD meta-analysis study population was warranted ([@ref70], [@ref69]). The CDC data, which were used as reference data for blood pressure, were retrieved from a multi-ethnic American population, in which all races were represented ([@ref46]). Therefore, we also expect reasonable generalizability of this reference data to our IPD meta-analysis study population.

After correction for multiple testing, we could not confirm a difference in insulin resistance in the total OPCOS population versus the controls. However, the increased 2 hour post-load insulin concentrations in female OPCOS might have implications later in life. For instance, the association between insulin concentrations during childhood and later life onset of type 2 diabetes mellitus has been investigated repeatedly ([@ref45]) and gave rise to conflicting results regarding the age at which such an association could be identified. Nonetheless, a significant association of increased insulin concentrations during childhood and later life type 2 diabetes mellitus, has been demonstrated regardless of BMI ([@ref48]; [@ref45]; [@ref58]).

The higher triglyceride concentrations observed in OPCOS may seem unfavorable. Nevertheless, increased lipid levels during childhood do not appear to predict unfavorable lipid profiles in adulthood ([@ref39]). We observed lower LDL-cholesterol and total cholesterol concentrations in female OPCOS in comparison with female controls. HDL-cholesterol concentrations in female OPCOS seem higher in daughters of women with PCOS compared to controls. The higher HDL-cholesterol in OPCOS might seem contradictory, since HDL-cholesterol may play a protective role in developing CVD in later life ([@ref3]). A Scandinavian study, however, suggests that the adults with the highest ranges of HDL-cholesterol actually may have an increased chance for CVD ([@ref40]). This is a potential explanation for our finding. But caution is warranted, since our study does not provide sufficient data to predict lipid profiles of OPCOS in adulthood. It also should be noted that there may be a sexual dimorphism regarding the expression of both insulin and lipids in the offspring of women diagnosed with PCOS, with an early appearance of hyperlipidemia and hyperinsulinemia in girls and a normal insulin and lipid profile in boys. This sexual dimorphism in both insulin and lipids has been reported earlier in normal adolescent girls compared to boys ([@ref5]). Thus, biomarkers in daughters and sons of women with PCOS seem to be modulated in part by the naturally occurring biological differences related to sex ([@ref34]; [@ref42]; [@ref19]). Sex differences in physical activity could also influence cardiometabolic outcome in offspring ([@ref1]). Supporting for this presumed sexual dimorphism comes from the higher 2 hour post-load insulin in OPCOS females compared to male OPCOS ([Supplementary Table SIV](#sup3){ref-type="supplementary-material"}).

It has been hypothesized that offspring health is determined by an interplay between genetic and environmental factors ([@ref28]). The Barker hypothesis proposes that early genetic adaptation to suboptimal conditions *in utero* may translate into adverse health later in life ([@ref4]). The onset of CVD has been observed in childhood. For instance, a post-mortem study in human adolescents and young adults who died from external injury, revealed the existence of manifest atherosclerosis early in life ([@ref47]). In contrast to these findings, we were unable to observe an increased metabolic sum score during childhood in OPCOS compared to controls. Our sample size may still be too small to detect subtle differences. We used a composite outcome: two variants of the metabolic sum score (arbitrarily defined as the sum of BMI or waist-to-height ratio, SBP, fasting and post-load insulin or glucose, triglycerides and HDL-cholesterol (metabolic sum score-1), or the sum of waist-to-height ratio, SBP, glucose, triglycerides, and HDL-cholesterol (metabolic sum score-2)) to mimic the multifactorial origin of CVD, as previously described (([@ref54]), personal communication). Both vascular and metabolic factors contribute to the onset of CVD (([@ref54]), personal communication).

The mechanisms underlying potential differences between OPCOS and healthy controls are diverse and incompletely understood ([@ref27]). Maternal overweight induces the transport of glucose, free fatty acids and amino acids to the fetus ([@ref68]). Metabolic and adipocyte function could thereby be altered and influence the development of offspring ([@ref17]). Conflicting theories have been put forward regarding the role of maternal androgens. It is suggested that hyperandrogenemia of the mother has a limited influence on the fetus due to the placental aromatase activity, which converts maternal androgens to estrogens ([@ref60]). However, the changing activities of placental enzymes diminish the conversion of androgens to estrogens, which could in theory lead to an increased testosterone supply from the placenta. This theory was not confirmed in two studies in which cord-blood testosterone was measured with liquid chromatography--tandem mass spectrometry assays ([@ref8]; [@ref14]). Studies in women with PCOS revealed macroscopic and microscopic alterations of the placenta, suggesting a deviant intrauterine environment compared to healthy controls ([@ref41]; [@ref53]). A small study of PCOS suggested that amniotic fluid androgen concentrations were elevated ([@ref52]). This was only observed in women pregnant of a female fetus, again suggesting potential sexual dimorphism ([@ref52]). Unfortunately, our data do not allow the elucidation of any causal mechanism for the alterations in OPCOS.

Owing to the age criteria applied in this IPD meta-analysis, puberty does play a role in this study. It is well known that puberty affects serum markers and, specifically, an early onset of puberty could influence the cardiometabolic profile ([@ref30]). Of the included studies, we know that the Chilean research group excluded girls with precocious pubarche. Data on puberty of the offspring were recorded in the American and Chilean offspring only and reported in our baseline table ([Table II](#TB2){ref-type="table"}). Tanner stages across studies appeared to be quite similar. Dutch OPCOS were included at 2.5--4 and 6--8 years of age, therefore, we refrained from recording there pubertal status. We did not use Tanner stages in our analyses due to the selective reporting and missing values in the Tanner data in the included studies. Another reason for this was the inconsistent data on age at menarche in women with PCOS themselves. A recent large Scandinavian cohort study does not confirm a lower age at menarche in women with PCOS compared to controls, as often suggested ([@ref67]; [@ref35]).

To the best of our knowledge, the current study represents the first IPD meta-analysis concerning cardiometabolic health in OPCOS. Rigorous methodology was applied when analyzing the data. Presumably due to the large sample size we were able to detect distinct sex-differences, while previous individual studies among OPCOS mainly focused on females, with often limited sample size ([@ref63], [@ref62]; [@ref32]; [@ref18]).

Several limitations should also be considered when interpreting our study results. In the current study, we used international external reference sources to calculate sex- and age-dependent SDS for BMI and SBP, which represents both strength and a limitation. The additional correction for sex by using interaction terms and stratification methods may have resulted in an underestimation of differences between males and females. On the other hand, the external reference sources do increase the external validity to other study populations.

The stratified analyses in male and female offspring suggest that females are influenced more compared to males by having mothers with PCOS. It could also be the cases that we did not observe any differences among males because of a lower number of male offspring in our dataset.

Another limitation is the limited data obtained on the mode of conception, precluding the assessment of a possible influence of infertility treatment per se. The Chilean study group reported that only children who were conceived naturally were eligible for participation in the follow-up study ([@ref55]).

Further details on pregnancies and parental health were not available. Therefore, we were not able to detect differences in familial or genetic predisposition for CVD between OPCOS and controls. It is plausible that a compromised familial history on CVD does encourage participation in an offspring follow-up study and introduces a selection bias.

Last, we must emphasize that we were not able to rule out any influence of sampling time differences and inter-assay variability on serum markers. We were not able to analyze one similar sample in every participating laboratory and with the same assay used in all the studies. We minimized the effect of different assay use by applying a mixed effect model, in which we added a random effect for country of origin of the child.

In conclusion, we observed in the current IPD meta-analysis of children born from women diagnosed with PCOS subtle signs of a compromised cardiometabolic health, predominantly in female offspring. The unfavorable cardiovascular profile of women with PCOS at childbearing age may---next to a genetic predisposition---influence health of their offspring.

It appears crucial to be able to make a distinction between the effects of a genetic predisposition and suboptimal conditions during pregnancy when aiming to improve the future health of OPCOS ([@ref13]; [@ref24]). To achieve this, more high validity follow-up studies on OPCOS are necessary with clearly defined endpoints on cardiometabolic health.
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